The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary Involvement

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F24%3A73622534" target="_blank" >RIV/61989592:15110/24:73622534 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/24:00138636 RIV/00216305:26220/24:PU150581 RIV/65269705:_____/24:00079463 RIV/00098892:_____/24:10158607

Výsledek na webu

<a href="https://pneumonia.biomedcentral.com/articles/10.1186/s41479-023-00123-7" target="_blank" >https://pneumonia.biomedcentral.com/articles/10.1186/s41479-023-00123-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s41479-023-00123-7" target="_blank" >10.1186/s41479-023-00123-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary Involvement

Popis výsledku v původním jazyce

Rationale Persistent respiratory symptoms following Coronavirus Disease 2019 (COVID-19) are associated with residual radiological changes in lung parenchyma, with a risk of development into lung fibrosis, and with impaired pulmonary function. Previous studies hinted at the possible efficacy of corticosteroids (CS) in facilitating the resolution of post-COVID residual changes in the lungs, but the available data is limited.Aim To evaluate the effects of CS treatment in post-COVID respiratory syndrome patients.Patients and methods Post-COVID patients were recruited into a prospective single-center observational study and scheduled for an initial (V1) and follow-up visit (V2) at the Department of Respiratory Medicine and Tuberculosis, University Hospital Olomouc, comprising of pulmonary function testing, chest x-ray, and complex clinical examination. The decision to administer CS or maintain watchful waiting (WW) was in line with Czech national guidelines.Results The study involved 2729 COVID-19 survivors (45.7% male; mean age: 54.6). From 2026 patients with complete V1 data, 131 patients were indicated for CS therapy. These patients showed significantly worse radiological and functional impairment at V1. Mean initial dose was 27.6 mg (SD +- 10,64), and the mean duration of CS therapy was 13.3 weeks (SD +- 10,06). Following therapy, significantly better improvement of static lung volumes and transfer factor for carbon monoxide (DLCO), and significantly better rates of good or complete radiological and subjectiveimprovement were observed in the CS group compared to controls with available follow-up data (n = 894).Conclusion Better improvement of pulmonary function, radiological findings and subjective symptoms were observed in patients CS compared to watchful waiting. Our findings suggest that glucocorticoid therapy could benefit selected patients with persistent dyspnea, significant radiological changes, and decreased DLCO.

Název v anglickém jazyce

The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary Involvement

Popis výsledku anglicky

Rationale Persistent respiratory symptoms following Coronavirus Disease 2019 (COVID-19) are associated with residual radiological changes in lung parenchyma, with a risk of development into lung fibrosis, and with impaired pulmonary function. Previous studies hinted at the possible efficacy of corticosteroids (CS) in facilitating the resolution of post-COVID residual changes in the lungs, but the available data is limited.Aim To evaluate the effects of CS treatment in post-COVID respiratory syndrome patients.Patients and methods Post-COVID patients were recruited into a prospective single-center observational study and scheduled for an initial (V1) and follow-up visit (V2) at the Department of Respiratory Medicine and Tuberculosis, University Hospital Olomouc, comprising of pulmonary function testing, chest x-ray, and complex clinical examination. The decision to administer CS or maintain watchful waiting (WW) was in line with Czech national guidelines.Results The study involved 2729 COVID-19 survivors (45.7% male; mean age: 54.6). From 2026 patients with complete V1 data, 131 patients were indicated for CS therapy. These patients showed significantly worse radiological and functional impairment at V1. Mean initial dose was 27.6 mg (SD +- 10,64), and the mean duration of CS therapy was 13.3 weeks (SD +- 10,06). Following therapy, significantly better improvement of static lung volumes and transfer factor for carbon monoxide (DLCO), and significantly better rates of good or complete radiological and subjectiveimprovement were observed in the CS group compared to controls with available follow-up data (n = 894).Conclusion Better improvement of pulmonary function, radiological findings and subjective symptoms were observed in patients CS compared to watchful waiting. Our findings suggest that glucocorticoid therapy could benefit selected patients with persistent dyspnea, significant radiological changes, and decreased DLCO.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

<a href="/cs/project/NU22-A-105" target="_blank" >NU22-A-105: Prediktivní biomarkery závažnosti a odpovědi na terapii COVID-19</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pneumonia

ISSN

2200-6133

e-ISSN

2200-6133

Svazek periodika

16

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

AU - Austrálie

Počet stran výsledku

10

Strana od-do

2

Kód UT WoS článku

001156289200001

EID výsledku v databázi Scopus

—